Predictors of response to second-line endocrine therapy for breast cancer
about
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus.Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer.Selection of Primary Breast Cancer Patients for Adjuvant Endocrine Therapy – is Oestrogen Receptor Alone Adequate?
P2860
Predictors of response to second-line endocrine therapy for breast cancer
description
article
@en
im September 1997 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 1997
@uk
name
Predictors of response to second-line endocrine therapy for breast cancer
@en
Predictors of response to second-line endocrine therapy for breast cancer
@nl
type
label
Predictors of response to second-line endocrine therapy for breast cancer
@en
Predictors of response to second-line endocrine therapy for breast cancer
@nl
prefLabel
Predictors of response to second-line endocrine therapy for breast cancer
@en
Predictors of response to second-line endocrine therapy for breast cancer
@nl
P2093
P2860
P50
P356
P1476
Predictors of response to second-line endocrine therapy for breast cancer
@en
P2093
C W Elston
J F Robertson
P C Willsher
R I Nicholson
R W Blamey
P2860
P2888
P304
P356
10.1023/A:1005828731462
P407
P577
1997-09-01T00:00:00Z
P6179
1018344209